Authors:
Alvan, G
Bertilsson, L
Dahl, ML
Ingelman-Sundberg, M
Sjoqvist, F
Citation: G. Alvan et al., Moving toward genetic profiling in patient care: The scope and rationale of pharmacogenetic/ecogenetic investigation, DRUG META D, 29(4), 2001, pp. 580-585
Authors:
Edlund, C
Alvan, G
Barkholt, L
Vacheron, F
Nord, CE
Citation: C. Edlund et al., Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora, J ANTIMICRO, 46(5), 2000, pp. 741-749
Authors:
Phillips, K
Howard, DA
Bentley, MC
Alvan, G
Citation: K. Phillips et al., Assessment of environmental tobacco smoke and respirable suspended particle exposures for nonsmokers in Basel by personal monitoring, ATMOS ENVIR, 33(12), 1999, pp. 1889-1904
Authors:
Sandwall, P
Lo, MW
Jonzon, B
Dalen, P
Furtek, C
Ritter, M
Alvan, G
McCrea, J
Sjoqvist, F
Citation: P. Sandwall et al., Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P4502C19), EUR J CL PH, 55(4), 1999, pp. 279-283